capecitabine has been researched along with Heart Failure in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambesh, P; Hollander, G; Kamholz, S; Obiagwu, C; Shani, J; Shetty, V; Zivari, K | 1 |
| Aoyagi, H; Hasegawa, K; Isogai, J; Kaneko, J; Maejima, S; Matsui, T; Yoshida, T | 1 |
| Kok, WE; Koopman, M; Kwakman, JJ; Mol, L; Punt, CJ; Simkens, LH | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Schwetz, BA | 1 |
5 other study(ies) available for capecitabine and Heart Failure
| Article | Year |
|---|---|
Rapidly developing heart failure from capecitabine cardiotoxicity: a case study.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Heart Failure; Humans; Male | 2018 |
[A case in which XELOX plus bevacizumab chemotherapy was effective in an elderly patient with heart failure and multiple liver metastases after sigmoidectomy].
Topics: Abdominal Abscess; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Deoxycytidine; Female; Fluorouracil; Heart Failure; Humans; Intestinal Perforation; Liver Neoplasms; Oxaloacetates; Sigmoid Neoplasms | 2013 |
Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Bevacizumab; Capecitabine; Carcinoma; Cardiotoxicity; Chest Pain; Colorectal Neoplasms; Heart Failure; Humans; Incidence; Myocardial Infarction; Myocardial Ischemia; Neoplasm Metastasis; Netherlands; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Retrospective Studies | 2017 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
From the Food and Drug Administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diethylhexyl Phthalate; Docetaxel; Female; Financing, Government; Fluorouracil; Heart Failure; Humans; Male; Orphan Drug Production; Pacemaker, Artificial; Paclitaxel; Spermatogenesis; Taxoids; Testis; United States; United States Food and Drug Administration | 2001 |